Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
ONC Quote, Financials, Valuation and Earnings
Last price:
$296.00
Seasonality move
:
-2.62%
Day range:
$293.70 - $300.60
52-week range:
$196.45 - $385.22
Dividend yield:
0%
P/E ratio:
118.52x
P/S ratio:
6.33x
P/B ratio:
8.25x
Volume:
355.8K
Avg. volume:
273.2K
1-year change:
16.21%
Market cap:
$33.1B
Revenue:
$5.4B
EPS (TTM):
$2.52
Analysts' Opinion
-
Consensus RatingBeOne Medicines Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $409.68, BeOne Medicines Ltd. has an estimated upside of 37.03% from its current price of $299.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $250.00 representing 16.39% downside risk from its current price of $299.02.
Fair Value
-
According to the consensus of 18 analysts, BeOne Medicines Ltd. has 37.03% upside to fair value with a price target of $409.68 per share.
ONC vs. S&P 500
-
Over the past 5 trading days, BeOne Medicines Ltd. has underperformed the S&P 500 by -14.99% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BeOne Medicines Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BeOne Medicines Ltd. has grown year-over-year revenues for 15 quarters straight. In the most recent quarter BeOne Medicines Ltd. reported revenues of $1.5B.
Earnings Growth
-
BeOne Medicines Ltd. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter BeOne Medicines Ltd. reported earnings per share of $0.58.
Enterprise value:
30.5B
EV / Invested capital:
4.79x
Price / LTM sales:
6.33x
EV / EBIT:
68.01x
EV / Revenue:
5.69x
PEG ratio (5yr expected):
--
EV / Free cash flow:
33.00x
Price / Operating cash flow:
36.69x
Enterprise value / EBITDA:
51.65x
Gross Profit (TTM):
$4.6B
Return On Assets:
4.24%
Net Income Margin (TTM):
5.37%
Return On Equity:
7.54%
Return On Invested Capital:
5.51%
Operating Margin:
12.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.5B | $3.8B | $5.4B | $1.1B | $1.5B | |
| Gross Profit | $2B | $3.1B | $4.6B | $932.9M | $1.3B | |
| Operating Income | -$1.2B | -$567.9M | $448.5M | -$79.1M | $185.8M | |
| EBITDA | -$1.1B | -$396.3M | $590.5M | -$29.1M | $222M | |
| Diluted EPS | -$8.50 | -$6.13 | $2.52 | -$1.42 | $0.58 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.6B | $5.2B | $4.2B | $4B | $6.2B | |
| Total Assets | $8.5B | $6.4B | $5.8B | $5.9B | $8.2B | |
| Current Liabilities | $1.6B | $1.5B | $1.8B | $2.2B | $1.8B | |
| Total Liabilities | $2.4B | $2B | $2.2B | $2.6B | $3.8B | |
| Total Equity | $6.1B | $4.4B | $3.5B | $3.3B | $4.4B | |
| Total Debt | $248M | $257.8M | $248.5M | $245.3M | $1.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.2B | -$140.6M | $1.1B | $75.2M | $418.9M | |
| Cash From Investing | $60M | -$548.4M | -$276.9M | -$93.6M | -$38.6M | |
| Cash From Financing | $416.5M | $193.4M | $1.1B | -$4.5M | $97.8M | |
| Free Cash Flow | -$1.7B | -$638M | $924.2M | -$17.3M | $381.2M | |
ONC
Sector
Market Cap
$33.1B
$25.5M
Price % of 52-Week High
77.62%
50%
Dividend Yield
0%
0%
Shareholder Yield
-1.12%
-1.62%
1-Year Price Total Return
16.21%
-17.47%
Beta (5-Year)
0.532
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$330.21
200-day SMA
Sell
Level
$311.02
Bollinger Bands (100)
Sell
Level
312.72 - 350.68
Chaikin Money Flow
Buy
Level
13.2M
20-day SMA
Sell
Level
$343.56
Relative Strength Index (RSI14)
Sell
Level
30.43
ADX Line
Sell
Level
21.04
Williams %R
Buy
Level
-92.7637
50-day SMA
Sell
Level
$335.35
MACD (12, 26)
Sell
Level
-7.88
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.3073)
Buy
CA Score
(Annual)
Level (0.3167)
Buy
Beneish M-Score
(Annual)
Level (-2.5079)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-3.2007)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Stock Forecast FAQ
In the current month, ONC has received 17 Buy ratings 0 Hold ratings, and 1 Sell ratings. The ONC average analyst price target in the past 3 months is $409.68.
-
Where Will BeOne Medicines Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BeOne Medicines Ltd. share price will rise to $409.68 per share over the next 12 months.
-
What Do Analysts Say About BeOne Medicines Ltd.?
Analysts are divided on their view about BeOne Medicines Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BeOne Medicines Ltd. is a Sell and believe this share price will drop from its current level to $250.00.
-
What Is BeOne Medicines Ltd.'s Price Target?
The price target for BeOne Medicines Ltd. over the next 1-year time period is forecast to be $409.68 according to 18 Wall Street analysts, 17 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ONC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BeOne Medicines Ltd. is a Buy. 17 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ONC?
You can purchase shares of BeOne Medicines Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BeOne Medicines Ltd. shares.
-
What Is The BeOne Medicines Ltd. Share Price Today?
BeOne Medicines Ltd. was last trading at $296.00 per share. This represents the most recent stock quote for BeOne Medicines Ltd.. Yesterday, BeOne Medicines Ltd. closed at $299.02 per share.
-
How To Buy BeOne Medicines Ltd. Stock Online?
In order to purchase BeOne Medicines Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ONC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ONC
Sector
P/E ratio
118.52x
22.53x
PEG ratio
--
-0.01x
P/B ratio
8.25x
1.79x
Price / LTM sales
6.33x
1.52x
Growth Metrics
ONC
Sector
Revenue growth
33.9%
3.33%
Earnings growth
140.65%
12%
Revenue (5-year growth)
76.94%
6.38%
Earnings forecast
$1.30
-$0.20
Profitability
ONC
Sector
Profitability FY 2025
$4.6B
$2.1M
Return on invested capital
5.51%
-33.43%
Return on assets
4.24%
-29.79%
Return on equity
7.54%
-39.36%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
6
Estimated Next Earnings Date
May
28
Balance Sheet
ONC
Sector
Total cash
$4.6B
$24.1M
Short term investments
--
$23.2M
Total assets
$8.2B
$69.8M
Long term debt
$1.9B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 5.82% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 3.55% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
